Oruka Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ORKA Nasdaq 2836 orukatx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Oruka Therapeutics, Inc.

Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001 - Jan 12th, 2026 5:00 am
Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Jan 6th, 2026 5:00 am
Oruka Therapeutics Announces New Board Member and Board Transition - Dec 11th, 2025 2:01 pm
ORKA-001 Trial Progress and US$180 Million PIPE Financing Might Change The Case For Investing In Oruka Therapeutics (ORKA) - Nov 15th, 2025 2:19 am
Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Nov 12th, 2025 2:05 pm
Wall Street Analysts Predict a 63.59% Upside in Oruka Therapeutics, Inc. (ORKA): Here's What You Should Know - Oct 29th, 2025 7:55 am
Oruka Therapeutics to Present at Multiple November Investor Conferences - Oct 29th, 2025 5:00 am
Barclays initiates coverage on U.S. small & mid-cap biotech stocks - Oct 13th, 2025 3:52 am
Oruka Therapeutics (ORKA) Is Up 33.2% After Announcing $1.25B Shelf Registration and $200M Offering - Oct 10th, 2025 10:18 am
MoonLake Crashes 90% On Mixed Results For Skin Disease Treatment - Sep 29th, 2025 2:24 pm
Oruka Therapeutics, Up 9%, Is Trying To Take On AbbVie's Biggest Moneymaker - Sep 17th, 2025 2:10 pm
Sector Update: Health Care Stocks Rise Premarket Wednesday - Sep 17th, 2025 7:16 am
Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Wednesday Ahead of Fed Policy Decision - Sep 17th, 2025 6:51 am
Oruka Therapeutics Says ORKA-001 Interim Early-Stage Data Supports Extended Dosing Intervals; Plans $180 Million Private Placement - Sep 17th, 2025 4:16 am
Oruka Therapeutics Announces $180 Million Private Placement - Sep 16th, 2025 11:02 pm
Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001 - Sep 16th, 2025 11:00 pm
Oruka Therapeutics (NASDAQ:ORKA) Is In A Good Position To Deliver On Growth Plans - Aug 15th, 2025 8:05 am
Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Aug 11th, 2025 2:04 pm
Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September - Jul 21st, 2025 5:00 am
Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer - Jul 1st, 2025 2:01 pm